SLN
NASDAQ HealthcareSilence Therapeutics Plc - American Depository Share
Biotechnology
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
�� 市场数据
| 价格 | $7.53 |
|---|---|
| 成交量 | 413,702 |
| 市值 | 355.67M |
| 贝塔系数 | 1.330 |
| RSI（14日） | 85.5 超买 |
| 200日均线 | $5.85 |
| 50日均线 | $5.71 |
| 52周最高 | $7.91 |
| 52周最低 | $2.91 |
| Forward P/E | -10.46 |
| Price / Book | 5.71 |
🎯 投资策略评分
SLN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (85/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SLN in your text
粘贴任何文章、记录或帖子 — 工具将提取 SLN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.